nature research

Corresponding author(s): Nadejda Tsankova

Last updated by author(s): Apr 30, 2021

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	nfirmed
		The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes		A description of all covariates tested
		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
		For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
\boxtimes		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code					
Data collection	10X Genomics was used to generate single-nucleus RNA sequencing libraries.				
Data analysis	Gene expression count matrices were generated with CellRanger (v3.1.5), processed and analyzed mainly using R package Seurat (v4.0.4). Seurat functions used: NormalizeData, RunPCA (2,000 variable genes), SCTransform, FindNeighbors, FindClusters, RunUMAP, CellCycleScoring, FindAllMarkers, AddModuleScore, FindTransferAnchors, Plot_cell_trajectory, AddMetaData. Regulons were analyzed using SCENIC (v1.1.2-01). Data visualization used ComplexHeatmap (v2.8.0), ggplot2 (v3.3.3), ggrepel (v0.9.1), ggvenn (v0.1.9), GraphPad Prism 9 (v9.3.1). Lineages were inferred using Monocle2 (v2.20.0), scVelo (v0.2.4), velocyto (v0.6), and Destiny (3.12.0). Doublets were removed via DoubletFinder (v2.0.3). Metascape (metascape.org, 2022 webversion) was used. Default parameters were used unless otherwise stated.				

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable: - Accession codes, unique identifiers, or web links for publicly available datasets

- A list of figures that have associated raw data
- A description of any restrictions on data availability

Single nucleus prenatal and adult RNA-seq data generated in this study have been deposited in the GEO database under the unique, accession code GSE### and will be deposited on the UCSC browser after publication.

Previously published data used in this study for comparative studies are available in the GEO and GSA databases under accession codes GSE131928 (Neftel et al 2019, GBM); HRA000348 and GSE144462 (Yang et al 2022, Fu et al 2021; human development), and GSE161132 (Li et al 2021; mouse development). Source data are provided with this paper (Fig. 1f, Fig. 2h, Fig. 2c, Fig. 2d, Fig. 2e, Fig. 2f, Fig. 2j, Fig. 2k, Fig. 3h, Fig. 3i, Fig. 4b, Fig. 4c, Fig. 4g, Fig. 4i, Fig. 7f, Supplemenatry Figs: 3a, 3b, 3c, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 5a, 5b, 6a, 6b, 6c, 6d, 6e).

Field-specific reporting

Life sciences

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

Sample size	This study used sample size of n=3-5 per developmental time point, 20,000 nuclei on average, which we determined to be statistically different
	using one-way ANOVA. We aimed for high temporal resolution in our study (4 developmental stages) and chose n=3 as the minimal sample size
Data exclusions	allowing for statistical testing using Student t-test. Statistical tests relying on nuclei numbers or Spearman correlation were also used. We excluded low-quality nuclei (< 400 genes, < 1,000 UMI counts), doublets, and nuclei with mitochondrial content greater than 15%.
Replication	We successfully validated newly discovered markers in situ in two different regions, in at least 3 independent experiments. We used 3 independent computational tools to infer lineage trajectories (scVelo, Monocle2, and Diffusion Maps). Similar results were seen with
Randomization	computational inferences when performed using 15% mitochondrial filter (revisions) and 25% mitochondrial filter (orginial submission). We used randomization in our scvelo trajectory analysis, which did not inlcude a starting lineage point.
Blinding	We were blinded by gestational age but not by anatomical region in our data integration and cell type annotation based on clustering. Our annotation methods included unbiased clustering in combination with cannonical marker expression to discover new prenatal cell types.

Reporting for specific materials, systems and methods

Methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study	n/a	Involved in the study
	Antibodies	\boxtimes	ChIP-seq
\boxtimes	Eukaryotic cell lines	\boxtimes	Flow cytometry
\boxtimes	Palaeontology and archaeology	\boxtimes	MRI-based neuroimaging
\boxtimes	Animals and other organisms		
	Human research participants		
\boxtimes	Clinical data		
\boxtimes	Dual use research of concern		

Antibodies

Antibodies used	Goat anti-EGFR, 1:50, R&D Systems AF231, lot#AUC1219011 Mouse anti-EGFR, 1:50, Abcam ab218383, lot#GR3290628-5
	Rabbit anti-SOX9, 1:200, Abcam ab185966, lot#GR3241181-4
	Rabbit anti-OLIG2, 1:50, Millipore AB9610, lot#3524758 Goat anti-OLIG2, 1:200, R&D Systems AF2418, lot#UPA0921091
	Rabbit anti-Ki67, 1:50, Invitrogen PA1-38032, lot#UI2842372A
	Rabbit anti-ZEB1, 1:500, Invitrogen PA5-82982, lot#XF3610564A
	Donkey anti-rabbit Alexa Fluor 488, Jackson ImmunoResearch Labs 711545152, lot#147626
Validation	Donkey anti-goat Alexa Fluor 594, Jackson ImmunoResearch Labs NC0281835, lot#125283 EGFR: Validation on human adult tissue for IHC-P provided on manufacturer's website and on our GBM tissue.
	SOX9: Validation on human prenatal tissue (9 gestational weeks) and cancer tissue for IHC-P provided on manufacturer's website.
	OLIG2: Validation on human glioblastoma tissue for IHC-P provided on manufacturer's website and on our GBM tissue.
	KI67: Validation on human cancer tissue for IHC-P provided on manufacturer's website and on our GBM tissue.
	ZEB1: validation on human cortex, glioma, and liver tissue for IHC-P provided on manufacturer's website.

Human research participants

Policy information about studies	involving human research participants
Population characteristics	15 postmortem prenatal (17-41 gestational weeks, 7F, 8M) and 3 postmortem adult (28-53 years, 2F, 1M) de-identified autopsy brain samples without pathological abnormalities.
Recruitment	All autopsies were done with written consent from the legal next-of-kin. Tissue collection was performed de-identified in accordance with the policies and regulation at the Icahn School of Medicine at Mount Sinai (ISMMS) and its Institutional Review Board. Only autopsy tissue secondary to unexpected and involuntary pregnancy loss was collected.

The Icahn School of Medicine Institutional Review Board considers autopsies as non-human subjects. Utilization of de-identified autopsy tissue was determined as non-human research by the ISMMS IRB, and approved under exemption HS#14-01007, in accordance with ethical conduct of research and compliance with fedearal, state, and institutional regulations.

e approval of the study protocol must also be provided in the manuscript.